Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single center, single arm, open label study of zanubrutinib,
lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse
large B-cell lymphoma.